• Explore /
  • Poster
  • / Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).

Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).

Abstract Poster

Authors

null

Walid Labib Shaib

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

Walid Labib Shaib , Manali Rupji , Tina Ashley Khair , Erwin L. Robin , Bassel F. El-Rayes , Timothy K. Huyck , Yuan Liu , Mohamad Bassam Sonbol , Tanios S. Bekaii-Saab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Pancreatic Cancer

Track

Pancreatic Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02581215

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 413)

DOI

10.1200/JCO.2021.39.3_suppl.413

Abstract #

413

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ashwin Reddy Sama

First Author: Dirk Strumberg

First Author: Gang Jin

First Author: Jeesun Yoon